Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Axitinib with Deferred Cytoreductive Nephrectomy in Advanced Clear Cell Renal Cell Carcinoma
NCT07776717Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Aug 2026
- Primary completion
- Dec 2027
01
Overview
A Phase 2 trial of toripalimab, axitinib in clear cell renal cell carcinoma (ccRCC), sponsored by Fudan University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
toripalimabaxitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07776717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07776717.